Copyright
©The Author(s) 2015.
World J Hepatol. Aug 8, 2015; 7(16): 2029-2040
Published online Aug 8, 2015. doi: 10.4254/wjh.v7.i16.2029
Published online Aug 8, 2015. doi: 10.4254/wjh.v7.i16.2029
Table 1 Circulating biomarker of hepatocellular carcinoma patients receiving antiangiogenic therapy
Treatment | Patient enrolled | Patient n | Predictive value | Prognostic value | Ref. |
Sorafenib, bevacizumab or thalidomide/oral 5FU | Elevated AFP | 72 | AFP responder (AFP decline > 20% in 4 wk) correlate with response | Early AFP responder: associate with PFS, OS | Shao et al[103] |
Sorafenib | Advanced | 30 | High baseline IL-8 correlates with PD; high Ang2, G-CSF, HGF, leptin correlate with shorter PFS | Miyahara et al[104] | |
Sorafenib | Advanced | 491 | High baseline sc-KIT, low HGF correlate with sorefinib response | Baseline Ang2, VEGF, AFP correlate with survival | Llovet et al[36] |
Sorafenib | Post-operative | 29 | High phosphor MET correlate with sorafenib resistance | Xiang et al[105] | |
Sunitinib | Advanced | 34 | High baseline AFP, IL-8, IL-6, SDF1, TNF correlate with PFS and OS; decreased IL-6, sc-KIT at day 14 correlate with improved PFS and OS | Zhu et al[24] | |
Sunitinib | Advanced | 37 | High baseline VEGFC correlates with response | High base VEGFC correlates with TTP; change in VEGFA, sVEGFR2 correlate with OS | Harmon et al[106] |
Sunitinib | Advanced | 23 | Decrease sVEGFR2 or TNF correlate, with decrease in Ktrans Kep; Decrease Ktrans, Kep at week 2 correlate with response | Sahani et al[107] | |
Bevacizumab | Advanced | 43 | Increase CEC on day 15 , low IL-8 correlate with disease control | High baseline IL-8, IL-6 correlate with short PFS, OS | Boige et al[108] |
Bevacizumab | Advanced | 59 | High Ang2, EGFR, endothelin 1, no acneiform rash correlate with poor outcome | Kaseb et al[109] | |
Thalidomide | Advanced | 47 | No predictive value of VEGF, bFGF, PlGF | Hsu et al[110] | |
Thalidomide/tegafur/uracil | Advanced | 43 | High IL-6, IL-8 correlate with short survival | Shao et al[111] | |
Thalidomide/radiotherapy | Advanced | 24 | No predictive value of VEGF, bFGF, IL-6, SDF1, TNF | Baseline IL-6, SDF1 at week 2 correlate with PFS. SDF1 at 1 mo post radiotherapy correlates with OS | Ch’ang et al[89] |
TSU68 | Advanced | 35 | High sVCAM1 correlates with response | Kanai et al[112] |
- Citation: Ch’ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol 2015; 7(16): 2029-2040
- URL: https://www.wjgnet.com/1948-5182/full/v7/i16/2029.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i16.2029